Best practice in the treatment of chronic hepatitis B: A summary of the European Viral Hepatitis Educational Initiative (EVHEI)

Journal of Hepatology

Volumn 47, Issue 4, 2007, Pages 588-597

  Thomas, Howard C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Immune clearance; Immune control and immune escape phases; Immune tolerance; Indications for treatment; Natural history of CHB; Pegylated interferon and nucleoside therapies

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON;

ADD ON THERAPY; ARTICLE; FOLLOW UP; HEALTH ECONOMICS; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; LIVER BIOPSY; LIVER CIRRHOSIS; MONOTHERAPY; PATIENT ASSESSMENT; PATIENT MONITORING; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; EUROPE; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 34548207856     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.07.017     Document Type: Article

References (26)

1. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
2. Carman W.F., Jacyna M.R., Hadziyannis S., Karayiannis P., McGarvey M.J., Makris A., et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2 (1989) 588-591
3. Chu C.M., Karayiannis P., Fowler M.J., Monjardino J., Liaw Y.F., and Thomas H.C. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 5 (1985) 431-434
4. Manno M., Cammà C., Schepis F., Bassi F., Gelmini R., Giannini F., et al. Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years. Gastroenterology 27 (2004) 756-763
5. Bortolotti F., Guido M., Bartolacci S., Cadrobbi P., Crivellaro C., Noventa F., et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 43 (2006) 556-562
6. Liaw Y.-F., Leung N., Guan R., Lau G.K., Merican I., McCaughan G., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25 (2005) 472-489
7. Keeffe E.B., Dieterich D.T., Han S.-H.B., Jacobson I.M., Martin P., Schiff E.R., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962
8. Lok A.S.F., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
9. Nguyen M.H., Trinh H., Garcia R.T., Ahmed A., and Keeffe E. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation. Hepatology 42 (2005) 593A
10. Lai M., Hyatt B., and Afdhal N. Role of liver biopsy in patients with normal ALT and high HBV DNA. Hepatology 42 (2005) 720A
11. Chevaliez S., Germanidis G., Roudot-Thoraval F., Bouvier-Alias M., Brillet R., Guerre F., et al. Diagnostic and prognostic value of virological parameters in a large homogenous cohort of patients with HBe-negative genotype D-related chronic hepatitis B. Hepatology 44 (2006) 254A
12. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., et al. Long-term follow-up of HbeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
13. Papatheodoridis G.V., Manesis E., and Hadziyannis S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34 (2001) 306-313
14. Nowak M.A., Bonhoeffer S., Hill A.M., Boehme R., Thomas H.C., and McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 93 (1996) 4398-4402
15. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
16. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
17. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
18. Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W., Woessner M., Stephenson S.L., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
19. Rizzetto M., Tassopoulos N.C., Goldin R.D., Esteban R., Santantonio T., Heathcote E.J., et al. Extended lamivudine treatment in patients with HbeAg-negative chronic hepatitis B. J Hepatol 42 (2005) 173-179
20. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
21. Hadziyannis S., Tassopoulos N., Chang T.T., Heathcote J., Kitis G., Rizzetto M., et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of treatment. Hepatology 42 (2005) 754A
22. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
23. Shouval D., Akarca U.S., Hatzis G., Kitis G., Lai C.L., Cheinquer H., et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027). J Hepatol 44 (2006) S21-S22
24. Lai C.-L., Gane E., Hsu C.-W., Thongsawat S., Wang Y., Chen Y., et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine. Hepatology 44 (2006) 222A
25. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
26. Hadziyannis S.J., Sevastianos V., Rapti I.N., and Tassopoulos N. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. Hepatology 44 (2006) 231A